ADMA BIOLOGICS INC (ADMA) Stock Price, Quote, News and Overview
NASDAQ:ADMA - Nasdaq - US0008991046 - Common Stock - Currency: USD
ADMA Quote, Performance and Key Statistics
23.52
+0.25 (+1.07%)
The current stock price of ADMA is 23.52 USD. In the past month the price increased by 20.93%. In the past year, price increased by 245.37%.
ADMA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About ADMA
Company Profile
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 677 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Company Info
ADMA BIOLOGICS INC
465 State Route 17
Ramsey NEW JERSEY 07446 US
CEO: Adam S. Grossman
Employees: 677
Phone: 12014785552
ADMA BIOLOGICS INC / ADMA FAQ
What is the stock price of ADMA BIOLOGICS INC today?
The current stock price of ADMA is 23.52 USD. The price increased by 1.07% in the last trading session.
What is the ticker symbol for ADMA BIOLOGICS INC stock?
The exchange symbol of ADMA BIOLOGICS INC is ADMA and it is listed on the Nasdaq exchange.
On which exchange is ADMA stock listed?
ADMA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ADMA BIOLOGICS INC stock?
10 analysts have analysed ADMA and the average price target is 25.78 USD. This implies a price increase of 9.6% is expected in the next year compared to the current price of 23.52. Check the ADMA BIOLOGICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ADMA BIOLOGICS INC worth?
ADMA BIOLOGICS INC (ADMA) has a market capitalization of 5.61B USD. This makes ADMA a Mid Cap stock.
How many employees does ADMA BIOLOGICS INC have?
ADMA BIOLOGICS INC (ADMA) currently has 677 employees.
What are the support and resistance levels for ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a support level at 19.37. Check the full technical report for a detailed analysis of ADMA support and resistance levels.
Is ADMA BIOLOGICS INC (ADMA) expected to grow?
The Revenue of ADMA BIOLOGICS INC (ADMA) is expected to grow by 17.21% in the next year. Check the estimates tab for more information on the ADMA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ADMA BIOLOGICS INC (ADMA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ADMA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ADMA, evaluating the profitability, health, valuation and growth aspects
- ADMA BIOLOGICS INC (ADMA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ADMA BIOLOGICS INC (ADMA) Sales and EPS estimates to see what analysts future expectations are.
- ADMA BIOLOGICS INC (ADMA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ADMA BIOLOGICS INC (ADMA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ADMA BIOLOGICS INC (ADMA) Stock Chart to make your own analysis
- ADMA BIOLOGICS INC (ADMA) Latest news and press-releases to stay up to date.
Does ADMA BIOLOGICS INC (ADMA) stock pay dividends?
ADMA does not pay a dividend.
When does ADMA BIOLOGICS INC (ADMA) report earnings?
ADMA BIOLOGICS INC (ADMA) will report earnings on 2025-05-07, after the market close.
What is the Price/Earnings (PE) ratio of ADMA BIOLOGICS INC (ADMA)?
The PE ratio for ADMA BIOLOGICS INC (ADMA) is 47.04. This is based on the reported non-GAAP earnings per share of 0.5 and the current share price of 23.52 USD. Check the full fundamental report for a full analysis of the valuation metrics for ADMA.
What is the Short Interest ratio of ADMA BIOLOGICS INC (ADMA) stock?
The outstanding short interest for ADMA BIOLOGICS INC (ADMA) is 5.78% of its float. Check the ownership tab for more information on the ADMA short interest.
ADMA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ADMA. When comparing the yearly performance of all stocks, ADMA is one of the better performing stocks in the market, outperforming 99.03% of all stocks.
ADMA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ADMA. ADMA has an excellent financial health rating, but there are some minor concerns on its profitability.
ADMA Financial Highlights
Over the last trailing twelve months ADMA reported a non-GAAP Earnings per Share(EPS) of 0.5. The EPS increased by 484.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 46.35% | ||
| ROA | 40.45% | ||
| ROE | 56.64% | ||
| Debt/Equity | 0.21 |
ADMA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ADMA. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 44.84% and a revenue growth 17.21% for ADMA